Santen Pharmaceutical Co., Ltd.

Medium-term Management Plan
FY2011-2013

May 11th, 2011
Akira Kurokawa
President & CEO
Core Value

Tenki ni sanyo-suru* 「天機に参与する」

We think carefully about what is essential, decide clearly what we should do, and act quickly.

Mission Statement

By focusing our efforts on ophthalmology and related areas, we develop scientific knowledge and organizational capabilities which are unique and original to Santen. We use our unique capabilities to contribute to patients and their loved ones, and consequently to society.

*Santen's original interpretation of a passage from chapter 22 of Zhongyong (The Doctrine of the Mean) by Confucius, meaning "exploring the secrets and mechanisms of nature in order to contribute to people's health"
Contents

1. Medium-term Management Plan FY2006-2010 Overview
2. Long-term Strategic Vision toward FY2020
4. Return to Shareholders Policy
1. Medium-term Management Plan FY2006-2010 Overview
Santen’s Global Development:
Creating new drug candidate and generating growth in promising regions by leveraging strength

1. Enhance the global strategic product pipeline through internal discovery and development, joint development projects and in-licensing efforts

2. Generate growth mainly in Japan, Northern/Eastern Europe, Russia and China. Focus U.S. activities on clinical and business development

3. Strengthen manufacturing bases

4. Strengthen human resources and organizational capabilities on a global basis
Sales and Operating Income for FY2006-2010

(JPY billions)

<table>
<thead>
<tr>
<th></th>
<th>Target</th>
<th>Results</th>
<th>Achievement %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales in FY10</td>
<td>115.0</td>
<td>110.8</td>
<td>96%</td>
</tr>
<tr>
<td>Operating income</td>
<td>32.0</td>
<td>30.7</td>
<td>96%</td>
</tr>
</tbody>
</table>

* Financial figures mentioned in this slide are consolidated basis.
Launched three new products as planned in MTP FY2006-2010 and succeeded an in-licensing product development.

<table>
<thead>
<tr>
<th>Domain</th>
<th>Launched in FY2006-2010</th>
<th>Development in Process</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glaucoma</td>
<td><strong>Tapros/Taflotan</strong></td>
<td>DE-112 Adenosine A$_{2A}$ Agonist</td>
<td>Phase1/2</td>
</tr>
<tr>
<td></td>
<td><strong>Cosopt (in-licensing)</strong></td>
<td>DE-111 Tafluprost/Timolol (combination)</td>
<td>Phase3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE-090 Lomerizine HCl</td>
<td>Phase2</td>
</tr>
<tr>
<td>Corneal Disease (Dry Eye)</td>
<td><strong>Diquas</strong></td>
<td>DE-101 Rivoglitazone</td>
<td>Phase1/2-2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE-105 Combination of peptides</td>
<td>Phase2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE-110 SEGRA</td>
<td>Phase2</td>
</tr>
<tr>
<td>Retinal Disease</td>
<td>DE-109 Sirolimus</td>
<td></td>
<td>Phase3</td>
</tr>
<tr>
<td></td>
<td>DE-102 Steroid DDS</td>
<td></td>
<td>Phase1/2</td>
</tr>
<tr>
<td>Infection, Allergy, RA</td>
<td>DE-108 Levofloxacin 1.5%</td>
<td></td>
<td>Approved</td>
</tr>
<tr>
<td></td>
<td>DE-114 Epinastine HCl</td>
<td></td>
<td>Phase3</td>
</tr>
<tr>
<td></td>
<td>DE-098 Apoptosis inducer</td>
<td></td>
<td>Phase2</td>
</tr>
<tr>
<td>IOL</td>
<td><strong>Eternity</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
ROE and DOE Overview

Target FY2010 Results

- **ROE**: 13% 14.5%
- **DOE**: 5% 5.3%

*Dividend assumption: 90 yen per share for FY2010*
### Summary in FY2006-2010 Period

Enhanced revenue base through new product launches in global markets.

<table>
<thead>
<tr>
<th>Target</th>
<th>Results</th>
<th>Achievement %</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Sales in FY2010: Yen 115 billion</td>
<td>→ Yen 110.8 billion</td>
<td>96%</td>
</tr>
<tr>
<td>- Operating income: Yen 32 billion</td>
<td>→ Yen 30.7 billion</td>
<td>96%</td>
</tr>
</tbody>
</table>

2. Three new products were launched as originally planned in FY2006-10 medium-term management plan.

3. Overseas businesses especially in Europe and China grew to deliver incomes.

4. Licensing-out initiatives to global companies such as Merck/MSD and Bausch & Lomb improved profitability.

5. Global product supply capability was strengthened by starting production at new Suzhou plant in China.

6. ROE and DOE were 14.5% and 5.3% respectively in FY2010.
Santen’s Strengths:

- Revenue base expands out to East Asia and Eastern Europe
- R&D capability for new product development to meet unmet medical needs

1. Unique expertise and high productivity as a specialized pharmaceutical company.

2. Leading positions in prescription ophthalmics markets in Japan and China.
   - Dominant sales and marketing base and competitiveness in Japan
   - Leading position in the fast growing Chinese market


4. Product pipeline in fast growing corneal, glaucoma and retinal segments.
2. Long-term Strategic Vision toward FY2020
Long-term Strategic Vision

To become a specialized pharmaceutical company with global presence

- Specialize in eye care and related categories in the fields where Santen has competitive advantage.

- Focus on R&D based on true customer needs* and contribute to innovation in therapeutic development.

- Establish our competitiveness and presence in global markets.

*Customer Needs: Unmet medical needs of patients, consumers, doctors and healthcare professionals.
Global Market Outlook

Global Prescription Ophthalmics Market

(JPY billions)

Rest of the world

Asia

Northern, Eastern Europe and Russia

Western Europe (five countries*)

US

Japan

Anti-infective and others

Dry eye

Glaucoma

Retina

2000 2010 2020

2,500

1,700

600

* UK, France, Germany, Spain, Italy

Source: Santen's analysis
Sustained Business Growth toward FY2020

Prescription Ophthalmics
Business in Market

- #1 in Japan and Asia
- Top 3 position globally

Overseas sales in 2020

- Up to 40 - 50% of Total Sales

Maximize New Product Value Globally

Establish & Reinforce Overseas Business Platform

Strengthen Domestic Business Platform and Competitiveness

2011

2020
Long-term Growth Scenario

- Demonstrate our presence in global prescription ophthalmic markets as a specialized pharmaceutical company
- Expand customer base and improve capabilities for product development to drive long-term growth

FY2011-2013 Growth Strategy
- New product value maximization
- Solid sales fundamentals development
- Taflotan growth and Solid sales fundamentals development

FY2014-2016 Growth Strategy
- Market creation
- Life Cycle Management/new product launch to meet local needs
- Customer base expansion
- New product launch globally

Long-term Growth Strategy
- Marketing to drive faster growth in Japan
- Marketing to make the best use of existing business platform in Asia/Europe
- Accelerated business development with new product launch in US/western Europe

Japan
Asia
Europe
US
3. Medium-term Management Plan
FY2011-2013
Medium-term Policies FY2011-2013

To become a specialized pharmaceutical company with global presence;

1. Promote global oriented research and development operation.

2. Boost domestic business by maximizing new product value and implementation of sales/marketing strategies.

3. Accelerate growth in both Asia and Europe by reinforcing marketing platform.

4. Establish global product supply system with existing 4 plants which enables to meet the emerging market needs.

5. Develop talents and organizational capabilities to promote “Creation and Innovation” on a globally level.
Investment Strategy for FY2011-2013

- Enrich a new product pipeline which drives mid to long term business growth
- Growth in Japan, Asia and Europe
- Increased investment for sustainable growth
### Medium-term Performance Targets

#### Performance Target for FY2013

<table>
<thead>
<tr>
<th>Category</th>
<th>Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consolidated sales</td>
<td>JPY 121 billion +</td>
</tr>
<tr>
<td>Operating income</td>
<td>JPY 31 billion +</td>
</tr>
<tr>
<td>Net income</td>
<td>JPY 20 billion +</td>
</tr>
<tr>
<td>R&amp;D Expenses</td>
<td>Approx. JPY 15.5 billion</td>
</tr>
<tr>
<td>DOE (Dividend on Equity)</td>
<td>Around 5%</td>
</tr>
</tbody>
</table>
1. **Invest strategically in late stage clinical trials**
   - Succeed in Phase-3 clinical trials.
   - Establish a US-centered global clinical operation system.
   - Extend product lines to meet local customer needs.

2. **Expand sales coverage in growing regions.**
   - Asia: primarily in China and Korea.
   - Europe: primarily in Germany, eastern Europe and Russia.

3. **Focused investment in business development.**
   - Enhance licensing and M&A activities.
R&D Strategy

Improve R&D capabilities to meet global market needs

1. Clinical Development
   1. Improve the probability of success and accelerate the speed of developments.
      - Transfer main process in establishing POC primarily in the US to prompt expansion of late stage trials in Europe and Japan, etc.
      - Fully reflect opinions/advices of clinical practitioners.
   2. Invest strategically in clinical trials.
      - R&D budget increased to JPY 14-16 billion; in response to increased number of late stage clinical trials.

2. Formulation/New Drug Discovery
   1. Life cycle management using Santen’s unique drug formulation technologies.
      - Focus on business development and new compound research functions.
**Blueprint of Product Launches**


<table>
<thead>
<tr>
<th>Domain</th>
<th>Launched in FY2006-2010</th>
<th>Launch Planned in FY2011-2013</th>
<th>Launch Planned after FY2014*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glaucoma</td>
<td><strong>Tapros/Taflotan</strong></td>
<td>DE-085 Tafluprost (China)</td>
<td>DE-112 Adenosine A$_{2A}$ Agonist</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>DE-111 Tafluprost/Timolol (combination)</td>
</tr>
<tr>
<td></td>
<td><strong>Cosopt</strong> (in-licensing)</td>
<td></td>
<td>DE-090 Lomerizine HCl</td>
</tr>
<tr>
<td>Corneal Disease (Dry Eye)</td>
<td><strong>Diquas</strong></td>
<td>DE-089 Diquafosol (China/Korea)</td>
<td>DE-101 Rivoglitazone</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>DE-105 Combination of peptides</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>DE-110 SEGRA</td>
</tr>
<tr>
<td>Retinal Disease</td>
<td></td>
<td></td>
<td>DE-109 Sirolimus</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>DE-102 Steroid DDS</td>
</tr>
<tr>
<td>Infection, Allergy, RA</td>
<td>DE-108 Levofloxacin 1.5%</td>
<td></td>
<td>DE-114 Epinastine HCl</td>
</tr>
<tr>
<td>IOL</td>
<td><strong>Eternity</strong></td>
<td><strong>Eternity</strong> Single piece/pre-loaded</td>
<td>DE-098 Apoptosis inducer</td>
</tr>
</tbody>
</table>
Japanese Prescription Ophthalmics: Strategy & Target

Drive business by new products value maximization

- Maximize product values in Glaucoma.
  - Tapros as a NTG* standard drug.
  - Cosopt as the best partner with PG**.
- Maintain the leading position in dry eye with various therapeutic proposals.
  - Hyalein as a standard drug for dry eye.
  - Diquas for stabilizing tear film.

Sales Target: Japanese Prescription Ophthalmics

(JPY billions)

<table>
<thead>
<tr>
<th>FY2010(Act.)</th>
<th>FY2013(MTP)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.2</td>
<td>30.0</td>
</tr>
</tbody>
</table>

Drug Price Revision Impact by NHI

- 4 New Products

* NTG: Normal Tension Glaucoma.
** PG: Prostaglandin Analogues, a type of glaucoma drugs including Tapros
Asian Business: Strategy & Target

Growth in fast growing markets

- **Increase sales by +15%**  
  (FY2011-2013, local currency basis)

- **China**
  - Strengthen marketing platform
  - Take advantage of fast growing market with new product launch such as Tafluprost
  - Reduce manufacturing costs by commencing a full-line operation at Suzhou plant

- **Korea**
  - Growth by Tapros, Cravit and Hyalein
  - Improve profitability by shifting to a direct promotion system and expanding sales coverage

- **Explore a new business base in Asia**

### Sales Target: Asian Business

<table>
<thead>
<tr>
<th>FY2010(Act.)</th>
<th>FY2013(MTP)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.6 (JPY billions)</td>
<td>10.4</td>
</tr>
</tbody>
</table>
European Business: Strategy & Target

- Increase sales by +10% in CAGR basis (FY2011-2013, at local currency)
- Business in Germany, Northern and Eastern European countries and Russia
  - Taflotan-driven business growth with launch of combination drugs
  - Strengthen in-licensing and local product development
  - Improve productivity by through combined cooperating manufacturing and sales efforts

Sales Target: European Business

<table>
<thead>
<tr>
<th></th>
<th>FY2010 (Act.)</th>
<th>FY2013 (MTP)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales Target</td>
<td>8.5</td>
<td>10.4</td>
</tr>
</tbody>
</table>

(JPY billions)
Product Supply Strategy

Develop an efficient global supply chain by optimizing the functions of 4 plants, and establish competitive cost structure

- Improve production capability based on global site planning.
  - Drive innovation in technology and process at Shiga plant as a core plant.
  - Improve the efficiency of production at Noto plant as a mother plant.
  - Start integrated production at Suzhou Plant in FY2012.
  - Increase capacities for new product supply to European markets and improve efficiency at the Tampere plant.

- Design an optimal global supply chain system from long term point of view.
  - Meet market needs, supply new products and realize competitive cost structure in emerging markets.
  - Explore candidates of new plants and review the functions of existing plants.
4. Return to Shareholders Policy
Policy for Return to Shareholders

- Stable return to shareholders
- Maintain sound and flexible financial position to enable product acquisitions and M&As for future growth

- Continue stable return per share
- Seek to maintain Dividend-on-equity (DOE) at around 5%, along with the income growth
- Effective use of share buybacks in flexible manner
Forward-Looking Statements

• Forecast or target figures in this material are not official earnings guidance but present the medium-term policies, etc. Official earnings guidance should be referred to in the disclosure of the annual financial report (Kessan Tanshin) in accordance with the rules set by Tokyo Stock Exchange.

• Information given in this announcement and accompanying documentation contains certain forward-looking statements concerning forecasts, projections and plans whose realization is subject to risk and uncertainty from a variety of sources. Actual results may differ significantly from forecasts.

• Business performance and financial condition are subject to the effects of medical regulatory changes made by the governments of Japan and other nations concerning medical insurance, drug pricing and other systems, and to fluctuations in market variables such as interest rates and foreign exchange rates.

• The process of drug research and development from discovery to final approval and sales is long, complex and uncertain. Individual compounds are subject to a multitude of uncertainties, including the termination of clinical development at various stages and the non-approval of products after a regulatory filing has been submitted. Forecasts and projections concerning new products take into account assumptions concerning the development pipelines of other companies and any co-promotion agreements, existing or planned. The success or failure of such agreements could affect business performance and financial condition significantly.

• Business performance and financial conditions could be affected significantly by a substantial drop in sales of a major drug, either currently marketed or expected to be launched, due to termination of sales as a result of factors such as patent expiry and complications, product defects or unforeseen side effects. Santen Pharmaceutical also sells numerous products under sales and/or manufacturing license from other companies. Business performance could be affected significantly by changes in the terms and conditions of agreements and/or the non-renewal of agreements.

• Santen Pharmaceutical is reliant on specific companies for supplies of certain raw materials used in production. Business performance could be affected significantly by the suspension or termination of supplies of such raw materials if such and event were to adversely affect supply capabilities for related final products.